CTOs on the Move

Lung Therapeutics

www.lungtx.com

 
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.lungtx.com
  • 1515 S. Capitol of Texas Highway Suite 402
    Austin, TX USA 78746
  • Phone: 737.802.1989

Executives

Name Title Contact Details

Funding

Lung Therapeutics raised $36M on 06/04/2019

Similar Companies

180 Life Sciences

Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation

HealthScape

HealthScape is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lysogene

Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children. Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen`s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers. Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.

Lacerta Therapeutics

Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases

Outpost Medicine

At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). ​Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.